Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
November 2025
The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy
Revvity Signals unveils Signals Clinical Solution to accelerate critical clinical trial insights
, /in Product News /by panglobalRevvity’s software and informatics division, Revvity Signals, has introduced the Signals Clinical solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics.
Azenta launches BioArc Ultra for automated, ultracold sample management
, /in Product News /by panglobalAzenta has launched their BioArc Ultra (the “Ultra”), a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance for large-scale sample management with the potential to forever change the landscape of biorepositories.
Novartis to acquire Calypso Biotech and CALY-002 therapeutic antibody
, /in E-News /by panglobalNovartis will acquire Calypso Biotech, a developer of Interleukin15 (IL-15) targeted therapies, for US$250 million plus a further $175 million based on the achievement of certain predetermined milestones.
Gilead Sciences set to acquire CymaBay Therapeutics for $4.3bn
, /in E-News /by panglobalGilead Sciences will acquire CymaBay Therapeutics for US$4.3 billion. The acquisition will see Gilead add CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, to their existing liver therapy portfolio.
PrecisionLife and Metrodora Institute partner to accelerate diagnosis, treatment of Long COVID, ME/CFS
, /in E-News /by panglobalPrecisionLife, and leading US multi-specialty healthcare center, and Metrodora Institute, are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases including Long COVID, ME/CFS, ALS, Sjögren’s syndrome, and many more. The partners will first develop and validate genotypic diagnostics that provide clinicians with an accurate […]
ENPICOM partners with Erasmus University Medical Center in effort to advance research of nanobodies against cancer
, /in E-News /by panglobalENPICOM, a bioinformatics software solutions provider, will collaborate with Erasmus Medical Center, Rotterdam, to identify and develop nanobodies against cancer by utilizing ENPICOM’s immune repertoire data analysis services and software solutions.
CN Bio appoints Joseph Parisi as US Director of Sales to support growing demand for OOC systems
, /in E-News /by panglobalCN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), has appointed Joseph Parisi as US Director of Sales. In his new role, Parisi will lead the expansion of the company’s sales and support activities for the US market to address the growing demand for new alternative methodologies […]
Pluri launches cell therapy CDMO
, /in E-News /by panglobalThe biotech company Pluri has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO.
CLSI introduces Country- Based Pricing to increase global access to laboratory standards
, /in E-News /by panglobalThe Clinical and Laboratory Standards Institute (CLSI) has implemented new Country-Based Pricing
Vetter becomes member of the German Association of Research-Based Pharmaceutical Companies
, /in E-News /by panglobalVetter, a globally operating contract development and manufacturing organization (CDMO), has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa recognizes the significant role that the pharmaceutical service provider plays in the field of complex injectable drugs.